Myasthenia gravis trials in Belgium

In Belgium 11 Also abroad 123

11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Where
Leuven
Age
18 years and over
People
59 worldwide
Run by
NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Anderlecht, Brugge, Gent, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Leuven, Liège
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Edegem, Gent
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Leuven, Liège
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Leuven, Liège
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Gent
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Leuven, Liège
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Leuven
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954
No phaseTaking people
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Where
Leuven
Age
18 years and over
People
680 worldwide
Run by
argenx
See details and how to joinNCT06298565
No phaseTaking people
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Where
Liège
Age
18 years and over
People
300
Run by
Centre Hospitalier Universitaire de Liege
See details and how to joinNCT07136844